- Home
- / Cerus
Cerus
Stock Price
$1.7
2024-10-29
Market Capitalization
$319.7 M
2024-10-29
Revenue
$233.8 M
FY, 2025
Cerus Summary
Company Summary
- Overview
- Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world.
- Type
- Public
- Status
- Active
- Founded
- 1991
- HQ
- Concord, CA, US | view all locations
- Website
- http://www.cerus.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Kevin D. Green, Vice President, Finance and Chief Financial Officer
Laurence M. Corash, Chief Scientific Officer
Dan Swisher, Chairman of the Board
Operating MetricsView all
Patents Issued
93
FY, 2016
LocationsView all
2 locations detected
Concord, CA HQ
United States
Concord Airport Plaza Building B, Concord Airport Plaza, 1220 Concord Ave
Amersfoort, UT
Netherlands
Stationsstraat 79-D
Cerus Financials
Summary Financials
- Revenue (Q1, 2026)
- $53.7M
- Net income (Q1, 2026)
- ($1.6M)
- Cash (Q1, 2026)
- $27.9M
- EBIT (Q1, 2026)
- ($354.0K)
- Enterprise value
- $356.7M